Bayer HealthCare Carve-Out Puts Focus On Pharmaceuticals, Kogenate
Bayer's carve-out of three of its business units and the divestiture of its plasma line will create an independent structure for its pharmaceuticals and hemophilia businesses
Bayer's carve-out of three of its business units and the divestiture of its plasma line will create an independent structure for its pharmaceuticals and hemophilia businesses